This segment focuses on the development, manufacturing, and commercialization of in vitro diagnostic (IVD) kits for the detection of calcifying nanoparticles (CNPs). Research and development activities include the creation of assays, antibodies, and reagents, with a focus on improving the sensitivity and specificity of CNP detection. Technologies employed include immunoassay techniques and potentially advanced imaging methods for CNP visualization. The primary therapeutic area is the early detection and monitoring of diseases associated with CNPs, including urological and cardiovascular conditions. The patient impact is improved disease management through early and accurate diagnosis. Market positioning is based on providing specialized diagnostic tools for a niche market. Future opportunities include expanding the range of diagnostic tests and exploring partnerships with clinical laboratories and healthcare providers. Regulatory and clinical aspects involve obtaining necessary approvals for IVD kits. This segment aims to provide tools for early detection and monitoring of diseases associated with CNPs.

This segment is dedicated to research and development efforts focused on the treatment of diseases related to calcifying nanoparticles (CNPs). Research activities include investigating the role of CNPs in urological diseases (chronic prostatitis/chronic pelvic pain syndrome, kidney stones, polycystic kidney diseases) and cardiovascular diseases. The company utilizes various methodologies, including cell culture, animal models, and potentially clinical trials, to identify and develop therapeutic interventions. The primary therapeutic areas are urology and cardiology, with the goal of developing treatments that target CNPs and mitigate their harmful effects. The patient impact is improved outcomes for individuals suffering from these conditions. Market positioning involves establishing a presence in the treatment of diseases associated with CNPs. Future opportunities include expanding the therapeutic pipeline and seeking strategic partnerships for clinical development and commercialization. Regulatory and clinical aspects involve conducting clinical trials and obtaining necessary regulatory approvals for therapeutic products. This segment aims to develop effective treatments for diseases associated with CNPs.